Related references
Note: Only part of the references are listed.2016 updated EULAR evidence-based recommendations for the management of gout
P. Richette et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout
R. L. Roberts et al.
PHARMACOGENOMICS JOURNAL (2017)
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States
Eric Jutkowitz et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Validation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B*58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions
Dinh Van Nguyen et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2017)
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout
Lisa K. Stamp et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Predicting allopurinol response in patients with gout
Daniel F. B. Wright et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
Thomas Bardin et al.
JOINT BONE SPINE (2016)
Impact of the HLA-B*58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions
Chau Yee Ng et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
New and Pipeline Drugs for Gout
Robert T. Keenan et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing
Jae-Woo Jung et al.
GENETICS IN MEDICINE (2015)
Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS)
H. -Y. Chou et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
Genetic markers associated with cutaneous adverse drug reactions to allopurinol: aysystematic review
Samantha Jarjour et al.
PHARMACOGENOMICS (2015)
Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea
Dong-Jin Park et al.
ARTHRITIS CARE & RESEARCH (2015)
Allopurinol Use and Risk of Fatal Hypersensitivity Reactions A Nationwide Population-Based Study in Taiwan
Chien-Yi Yang et al.
JAMA INTERNAL MEDICINE (2015)
Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin
Wen-Hung Chung et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population
Surasak Saokaew et al.
PLOS ONE (2014)
Understanding the dose-response relationship of allopurinol: predicting the optimal dosage
Garry G. Graham et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing
M. S. Hershfield et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012
Sheena N. Ramasamy et al.
DRUG SAFETY (2013)
Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study
Seoyoung C. Kim et al.
ARTHRITIS CARE & RESEARCH (2013)
Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008
Yanyan Zhu et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2012)
HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese
Zhi Hao Cao et al.
PHARMACOGENOMICS (2012)
Furosemide increases plasma oxypurinol without lowering serum urate-a complex drug interaction: implications for clinical practice
Lisa K. Stamp et al.
RHEUMATOLOGY (2012)
2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
Dinesh Khanna et al.
ARTHRITIS CARE & RESEARCH (2012)
Using Allopurinol Above the Dose Based on Creatinine Clearance Is Effective and Safe in Patients With Chronic Gout, Including Those With Renal Impairment
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2011)
Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate Level
L. K. Stamp et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis
A. F. Cristallo et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2011)
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
M. K. Reinders et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
Wichittra Tassaneeyakul et al.
PHARMACOGENETICS AND GENOMICS (2009)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis
Nahoko Kaniwa et al.
PHARMACOGENOMICS (2008)
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
MA Becker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients
J Chanard et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Share Paper
